Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3
#3PRI RANKED
Most Cited Paper
in Cancer-related Molecular Pathways
18 Months Post-Publication
Class of 2026
“Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3”
A research intelligence initiative by Pepkio
pri.pepkio.com
Topics
abemaciclib · nonsteroidal aromatase inhibitor · HR+ HER2− advanced breast cancer · MONARCH 3 · overall survival · progression-free survival · anastrozole · letrozole · postmenopausal women · initial therapy · visceral disease · chemotherapy-free survival · CDK4/6 inhibitor · endocrine therapy · Phase 3 trial · fulvestrant
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Cancer-related Molecular Pathways Papers, Class of 2026. https://pri.pepkio.com/top-papers/cancer-related-molecular-pathways/2026. Accessed 2026-10-24. Methodology Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459